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Treatment-related symptoms are common among patients with metastatic cancer and can 
result in distress, decrements in physical function, and unplanned hospitalizations.1,2 
Symptom management is a cornerstone of clinical practice, and both symptom management 
and quality of life are consistently among the highest priorities to patients with cancer and 
their caregivers.3,4 Typically, clinicians elicit symptom information at clinic visits through 
unstructured discussions. However, with this approach, care teams do not detect burdensome 
symptoms up to one half of the time, and clinicians’ symptom ratings have low reliability.5–7 
Under detection of symptoms occurs for several reasons. Visits with clinicians may be too 
infrequent or too short to adequately capture symptom burden. Patients may have trouble 
recalling how frequent or burdensome their symptoms have been in between visits due to 
recall bias.8,9 Communication between clinicians and patients may be hampered by status 
and educational differences, language barriers, expectations about clinical encounters, lack 
of trust, not feeling well, and more.10,11
One solution is to systematically screen for symptoms between visits by asking patients to 
complete weekly patient-reported outcome (PRO) measures about their pain, nausea, and 
other symptoms. PRO measures are the preferred approach for assessing symptoms across 
health care contexts because patients are in the best position to report on their own 
experiences and because PROs provide a more comprehensive understanding of those 
experiences.12 Routine use of PROs has been identified as a priority area by the President’s 
Cancer Panel and national oncology societies such as ASCO.13,14 However, health care 
systems lack roadmaps for how to change multiple system levels and infrastructures to 
integrate PRO measures into clinical workflow, which is an implementation problem. Thus, 
a critical need exists for comprehensive implementation strategies that address barriers and 
strengthen facilitators unique to each health care system.
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A growing body of evidence shows that the collection of PRO measures from patients and 
their review during visits yield better clinical outcomes. For example, use of symptom 
questionnaires increases communication between clinicians and patients, detection of 
problematic symptoms, and satisfaction with care.15–18 In a single-site randomized trial in 
the United States, > 700 patients who underwent chemotherapy were randomly assigned to 
complete weekly Web-based symptom questionnaires versus usual care. Patients in the 
intervention group who systematically completed symptom questionnaires were more likely 
to be alive at 1 year, were able to continue with treatment longer, and had fewer emergency 
department visits.19 Treating physicians received symptom reports at visits, and nurses 
received e-mail alerts when patients reported a worsening of 12 common symptoms (ie, 
predetermined clinical criteria were met). The PRO intervention showed the greatest benefits 
for patients with lower education and less computer experience,19 which suggests that health 
disparities could be reduced with PRO integration into clinical workflow.
A second phase III randomized trial in Europe was closed early for clear survival benefit for 
the intervention group, which completed weekly symptom questionnaires. At multiple sites, 
patients with metastatic lung cancer randomly assigned to complete weekly symptom 
questionnaires had a mean survival time of 19 months versus 12 months in usual care 
patients.20 Similar benefits have been shown in other randomized trials.21–24 The probable 
mechanism at work is that clinicians were made aware of symptom increases sooner and 
could then intervene earlier to avoid adverse and costly outcomes.
As more trials demonstrate efficacy and the idea of patient-centered care matures,25,26 
incorporation of symptom questionnaires into routine clinical workflow will become 
increasingly important for health care systems. Every US health care system faces this issue 
as the Centers for Medicare & Medicaid Services Electronic Health Record Incentive 
Program’s meaningful use requirements continue to increase annually.27 National (and 
international) oncology societies, federal agencies, and individual health care systems have a 
major opportunity to plan and implement a rollout of system-level changes over the next 5 
years to ensure that PROs are integrated into routine clinical workflow. This may require an 
evolution of organizational culture to emphasize the importance of PROs and adaption of 
electronic health record systems.
National oncology and PRO methodology societies and federal agencies have published 
recommendations for questionnaire implementation, but no comprehensive plans have been 
put forward. For instance, the International Society of Quality of Life Research28 and 
Snyder et al29 outlined a series of starter questions that health care systems can use to self-
assess their unique needs for PRO implementation planning. Similarly, the Department of 
Veterans Affairs has several recommendations for designing applications to capture patient-
generated data to enhance patient-clinician partnerships, including health system culture, 
data value, architecture, policy, data standards, clinical workflow, data visualization, and 
analytics and population reach.30
The National Cancer Institute recommends that the following 12 common symptoms be 
assessed across cancer types during clinical trials: fatigue, insomnia, pain, anxiety (includes 
worry), depression (includes sadness),anorexia (appetite loss), nausea, constipation, 
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diarrhea, dyspnea, cognitive problems, and sensory neuropathy.31 The idea is that practices 
can assess common symptoms and decide on additional PRO areas relevant for each cancer 
type.32,33 For instance, bladder and bowel issues are relevant in prostate and colorectal 
cancer but less relevant in breast cancer. At least one systematic review is needed that 
identifies all PRO and quality-of-life measures (general and disease specific) and then 
provides a menu of the best-performing scales in oncology practice. Oncology societies and 
federal agencies then can provide guidance on how to choose PRO measures so that results 
are comparable across health care systems.
This collection of recommendations is an excellent start to implementation planning, but 
more work that focuses on systems-level changes is needed. A newer field, implementation 
science, can guide societies, agencies, and health care systems to start to think through 
solutions to the system barriers they will face.34–36 Implementation strategies typically 
encompass six key stages: planning, educating, financing, restructuring, managing quality, 
and attending to the policy context.37 For the planning and educating stages, the involvement 
of all potential stakeholders, including patients, clinicians, practice staff, decision makers, 
quality officers, financial officers, informaticians, PRO methodologists, health services and 
researchers, will be critical. Health care innovation changes typically take 2 to 4 years for 
full implementation38; thus, planning should start early. Research on multidisciplinary teams 
with skill sets in clinical care, informatics, PRO methodology, and implementation science is 
needed to develop and evaluate comprehensive implementation plans that are sustainable.
Broad-level guidance is needed from societies and federal agencies, but each health care 
system and practice will need tailored implementation strategies that fit their unique needs. 
Implementation measures for health care have advanced significantly over the past 20 
years.39–42 Interdisciplinary research teams will be able to map implementation process and 
outcome measures to the challenges specific to PRO integration. More useful results will be 
obtained if research teams evaluate implementation strategies simultaneously at multiple 
levels (eg, patient, provider, care team workflow, medical record system) rather than treat 
them as separate interventions.42 In 6 to 8 years, this new field should be ready to develop 
cluster randomized trials with head-to-head comparisons of various implementation 
strategies to examine what works best in which context and for whom.
Three final issues that health care systems and research teams will need to consider are 
flexible workflows that allow for future change, the training of care team members on how 
to use PRO measures, and reduction of clinician burden. The idea of learning health care 
systems is that they continually improve processes as more data emerge from within the 
health care system itself and as national guidelines are updated for high-quality cancer are.43 
In other words, health care systems need to not only learn implementation strategies but also 
be flexible enough to de-adopt low-value clinical procedures that are no longer 
recommended or do not perform well in some contexts.44 A key piece to flexible workflows 
is the training of clinicians and staff on how to interpret PRO results for the specific 
questionnaires chosen and the best ways to discuss results with patients. PRO training could 
be incorporated into existing training needs, such as the Commission on Cancer’s training 
recommendation for interpreting psychosocial distress measures.45 This is one area where 
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oncology societies could make a big difference in ensuring high-quality training in PRO 
measures for clinical practice.
The redesign of clinical workflow also allows the opportunity to consider pieces that are no 
longer relevant in favor of adding PRO implementation. For example, clinicians spend a 
considerable amount of time in documenting quality performance measures.46 A lesser 
known benefit of integrating PRO measures into clinical workflow is that PRO results could 
be quality metrics in and of themselves.47,48 For example, similar practices could be 
compared on the percentage of patients who receive chemotherapy who report moderate to 
high pain.46–48 In this case, clinicians may be able to reduce performance metric 
documentation because PRO results would be available for practice comparisons. An 
emerging research issue in this area is which variables to adjust for to ensure fair 
comparisons (case-mix and risk adjustment).48
In summary, five key areas should be considered for comprehensive implementation 
planning of PRO integration into health care systems:
• A menu of implementation strategies that overcomes not only barriers that most 
systems face but also barriers and facilitators unique to each system;
• Multidisciplinary teams with all potential stakeholders represented during the 
planning and educating stages to ensure sustainability;
• Flexible workflows that allow for future implementation and de-adoption of low-
quality care;
• Careful consideration about the best ways to reduce burden on clinicians when 
changing workflow; and
• Training for clinicians and staff on PRO interpretation and how to discuss results 
with patients.
Acknowledgments
The production of this manuscript was funded by the Conquer Cancer Foundation Mission Endowment. Supported 
by Grant No. R25-CA116339 from the Cancer Care Quality Training Program and Grant No. R25-CA171994 from 
the Mentored Training in Dissemination and Implementation in Cancer project. We thank Leah Zullig, David 
Chambers, and Ramzi Salloum for reading a prior draft.
References
1. Henry DH, Viswanathan HN, Elkin EP, et al. Symptoms and treatment burden associated with 
cancer treatment: Results from a cross-sectional national survey in the U.S. Support Care Cancer. 
2008; 16:791–801. [PubMed: 18204940] 
2. Cleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer: Evidence for a core set of 
cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group 
Symptom Outcomes and Practice Patterns study. Cancer. 2013; 119:4333–4340. [PubMed: 
24114037] 
3. Butt Z, Rosenbloom SK, Abernethy AP, et al. Fatigue is the most important symptom for advanced 
cancer patients who have had chemotherapy. J Natl Compr Canc Netw. 2008; 6:448–455. [PubMed: 
18492460] 
Stover and Basch Page 4
J Oncol Pract. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by 
patients, family, physicians, and other care providers. JAMA. 2000; 284:2476–2482. [PubMed: 
11074777] 
5. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse 
effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. 
J Clin Oncol. 2004; 22:3485–3490. [PubMed: 15337796] 
6. Laugsand EA, Sprangers MA, Bjordal K, et al. Health care providers underestimate symptom 
intensities of cancer patients: A multicenter European study. Health Qual Life Outcomes. 2010; 
8:104. [PubMed: 20858248] 
7. Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. 
Qual Life Res. 2012; 21:1159–1164. [PubMed: 21984468] 
8. Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life assessment among 
men treated for prostate cancer. J Clin Oncol. 1999; 17:2882–2888. [PubMed: 10561366] 
9. Taminiau-Bloem EF, Van Zuuren FJ, Visser MRM, et al. Opening the black box of cancer patients’ 
quality-of-life change assessments: A think-aloud study examining the cognitive processes 
underlying responses to transition items. Psychol Health. 2011; 26:1414–1428. [PubMed: 
21736499] 
10. Rodin G, Mackay JA, Zimmermann C, et al. Clinician-patient communication: A systematic 
review. Support Care Cancer. 2009; 17:627–644. [PubMed: 19259706] 
11. Epstein, RM., Street, RL, Jr. Patient-Centered Communication in Cancer Care: Promoting Healing 
and Reducing Suffering. Bethesda, MD: National Cancer Institute; 2007. NIH Publication No. 
07-6225
12. National Comprehensive Cancer Network. NCCN guidelines for supportive care. http://
www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive
13. President’s Cancer Panel. Connected Health: Improving Patients’ Engagement and Activation for 
Cancer-Related Outcomes: President’s Cancer Panel 2014–2015 Series. http://deainfo.nci.nih.gov/
advisory/pcp/glance/ConnectedHealth14–15.pdf
14. Basch E, Snyder C, McNiff K, et al. Patient-reported outcome performance measures in oncology. 
J Oncol Pract. 2014; 10:209–211. [PubMed: 24756142] 
15. Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical 
practice: A scoping review of use, impact on health outcomes, and implementation factors. Ann 
Oncol. 2015; 26:1846–1858. [PubMed: 25888610] 
16. Valderas JM, Kotzeva A, Espallargues M, et al. The impact of measuring patient-reported 
outcomes in clinical practice: A systematic review of the literature. Qual Life Res. 2008; 17:179–
193. [PubMed: 18175207] 
17. Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient reported 
outcome measures on patients, providers and health organisations in an oncologic setting. BMC 
Health Serv Res. 2013; 13:211. [PubMed: 23758898] 
18. Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-
reported outcome measures toward improvement of patient outcomes, processes of care, and health 
service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014; 
32:1480–1501. [PubMed: 24711559] 
19. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during 
routine cancer treatment: A randomized controlled trial. J Clin Oncol. 2016; 34:557–565. 
[PubMed: 26644527] 
20. Denis F, Lethrosne C, Pourel N, et al. Overall survival in patients with lung cancer using a Web-
application–guided follow-up compared to standard modalities: Results of phase III randomized 
trial. J Clin Oncol. 2016; 34(suppl) abstr LBA9006. 
21. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice 
improves communication and patient well-being: A randomized controlled trial. J Clin Oncol. 
2004; 22:714–724. [PubMed: 14966096] 
22. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and 
patient-physician communication: A randomized controlled trial. JAMA. 2002; 288:3027–3034. 
[PubMed: 12479768] 
Stover and Basch Page 5
J Oncol Pract. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
23. Cleeland CS, Wang XS, Shi Q, et al. Automated symptom alerts reduce postoperative symptom 
severity after cancer surgery: A randomized controlled clinical trial. J Clin Oncol. 2011; 29:994–
1000. [PubMed: 21282546] 
24. Berry DL, Blumenstein BA, Halpenny B, et al. Enhancing patient-provider communication with 
the electronic self-report assessment for cancer: A randomized trial. J Clin Oncol. 2011; 29:1029–
1035. [PubMed: 21282548] 
25. Committee on Quality of Health Care in America, Institute of Medicine. Crossing the Quality 
Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 
2001. 
26. Rosenzveig A, Kuspinar A, Daskalopoulou SS, et al. Toward patient-centered care: A systematic 
review of how to ask questions that matter to patients. Medicine (Baltimore). 2014; 93:e120. 
[PubMed: 25396331] 
27. Centers for Medicare & Medicaid Services. Medicare and Medicaid EHR Incentive Program 
basics. https://www.cms.gov/regulations-and-guidance/legislation/ehrincentiveprograms/
basics.html
28. Aaronson, N., Elliott, T., Greenhalgh, J., et al. User’s Guide to Implementing Patient-Reported 
Outcomes Assessment in Clinical Practice. 2015. Version 2http://www.isoqol.org/UserFiles/
2015UsersGuide-Version2.pdf
29. Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes 
assessment in clinical practice: A review of the options and considerations. Qual Life Res. 2012; 
21:1305–1314. [PubMed: 22048932] 
30. Woods SS, Evans NC, Frisbee KL. Integrating patient voices into health information for self-care 
and patient-clinician partnerships: Veterans Affairs design recommendations for patient-generated 
data applications. J Am Med Inform Assoc. 2016; 23:491–495. [PubMed: 26911810] 
31. Reeve BB, Mitchell SA, Dueck AC, et al. Recommended patient-reported core set of symptoms to 
measure in adult cancer treatment trials. J Natl Cancer Inst. 2014; 106:dju129. [PubMed: 
25006191] 
32. Chera BS, Eisbruch A, Murphy BA, et al. Recommended patient-reported core set of symptoms to 
measure in head and neck cancer treatment trials. J Natl Cancer Inst. 2014; 106:dju127. [PubMed: 
25006189] 
33. Chen RC, Chang P, Vetter RJ, et al. Recommended patient-reported core set of symptoms to 
measure in prostate cancer treatment trials. J Natl Cancer Inst. 2014; 106:dju132. [PubMed: 
25006192] 
34. Flottorp SA, Oxman AD, Krause J, et al. A checklist for identifying determinants of practice: A 
systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable 
improvements in healthcare professional practice. Implement Sci. 2013; 8:35. [PubMed: 
23522377] 
35. Brownson, RC., Colditz, GA., Proctor, EK. Dissemination and Implementation Research in Health: 
Translating Science to Practice. 1. Oxford, UK: Oxford University Press; 2012. 
36. Chaudoir SR, Dugan AG, Barr CH. Measuring factors affecting implementation of health 
innovations: A systematic review of structural, organizational, provider, patient, and innovation 
level measures. Implement Sci. 2013; 8:22. [PubMed: 23414420] 
37. Powell BJ, McMillen JC, Proctor EK, et al. A compilation of strategies for implementing clinical 
innovations in health and mental health. Med Care Res Rev. 2012; 69:123–157. [PubMed: 
22203646] 
38. Grol, R., Wensing, M., Eccles, M., et al. Improving Patient Care: The Implementation of Change in 
Health Care. New York, NY: Wiley; 2013. 
39. Rabin BA, Lewis CC, Norton WE, et al. Measurement resources for dissemination and 
implementation research in health. Implement Sci. 2016; 11:42. [PubMed: 27000147] 
40. Curran GM, Bauer M, Mittman B, et al. Effectiveness-implementation hybrid designs: Combining 
elements of clinical effectiveness and implementation research to enhance public health impact. 
Med Care. 2012; 50:217–226. [PubMed: 22310560] 
41. Glasgow RE, Emmons KM. How can we increase translation of research into practice? Types of 
evidence needed. Annu Rev Public Health. 2007; 28:413–433. [PubMed: 17150029] 
Stover and Basch Page 6
J Oncol Pract. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
42. Emmons KM, Weiner B, Fernandez ME, et al. Systems antecedents for dissemination and 
implementation: A review and analysis of measures. Health Educ Behav. 2012; 39:87–105. 
[PubMed: 21724933] 
43. Abernethy AP, Ahmad A, Zafar SY, et al. Electronic patient-reported data capture as a foundation 
of rapid learning cancer care. Med Care. 2010; 48:S32–S38. suppl 6. [PubMed: 20473201] 
44. Niven DJ, Mrklas KJ, Holodinsky JK, et al. Towards understanding the de-adoption of low-value 
clinical practices: A scoping review. BMC Med. 2015; 13:255. [PubMed: 26444862] 
45. Commission on Cancer. 3.2 – Psychosocial distress screening. Cancer Program Standards: 
Ensuring Patient-Centered Care (ed 2016). https://www.facs.org/~/media/files/quality
%20programs/cancer/coc/2016%20coc%20standards%20manual_interactive%20pdf.ashx
46. Casalino LP, Gans D, Weber R, et al. US physician practices spend more than $15.4 billion 
annually to report quality measures. Health Aff (Millwood). 2016; 35:401–406. [PubMed: 
26953292] 
47. Basch E, Torda P, Adams K. Standards for patient-reported outcome-based performance measures. 
JAMA. 2013; 310:139–140. [PubMed: 23839744] 
48. Stover AM, Basch EM. Using patient-reported outcome measures as quality indicators in routine 
cancer care. Cancer. 2016; 122:355–357. [PubMed: 26619153] 
Stover and Basch Page 7
J Oncol Pract. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
